RE:RE:RE:RE:RE:HOLD ON TIGHTLYThanks mden2. I am hoping for the best but we are all concerned. If there is 'something big' as you state, wouldn't Crowe have stepped away from this company months ago ?
mden2 wrote: They are generally the same, it usually comes down to issues where there management discretion and opinion on certain issues. I am not in the pharma industry but where I can see an issue arise is when is revenue a revenue, I mean when does title transfer? Another one is which methodology is used to value assets and liabilities, IFRS is a lot more onerous and time consuming, ie.. using discounting cash flow for Income producing units for valuation, probably I am assuming for goodwill purposes. It gets very complicated and confusing. I am not a big fan of IFRS, it is just a big cash grab from the big auditing firms. But having said all this, this should have been resolved a long time ago. I can see if this was a private company but for this to happen to a publicly listed company with all of the negative press on the industry, it has to be something big, if it was not, they would have resolved it a long time ago. You never know, when this comes out, it may be something about nothing, BUT if that is the case, why so long?